Business Wire

TIP harnesses ADVA for successful trial of end-to-end open optical network

Share

ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) and Ensemble Controller network management and SDN domain controller system played a key role in a successful Telecom Infra Project (TIP) open optical networking proof of concept (PoC). The demo is a crucial step for vendor-neutral disaggregated solutions with operators able to mix and match best-in-breed technology and leverage different product lifecycles. The PoC showed how multi-vendor network components can be managed by a unified software-defined networking (SDN) control system. Specifically designed for easy interoperability, ADVA’s FSP 3000 OLS and Ensemble Controller ensured seamless integration into the open environment, including third-party terminals. The PoC will be on display at OFC at the virtual Demo Zone from June 7 to 11.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005193/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s technology played a crucial role in TIP’s open optical networking PoC (Photo: Business Wire)

“This PoC is an important milestone in the journey to fully open and disaggregated optical networking. It offers new levels of visibility and a way to manage the entire multi-vendor environment. With the power to seamlessly integrate components from different suppliers, network operators can confidently deploy best-in-class infrastructure that meets their exact requirements,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 OLS was central to the demo. It’s a truly open solution that gives operators freedom to build multi-supplier architectures and then evolve and optimize each network layer separately. With our Ensemble Controller also playing a major role – providing network management and programmatic SDN control – this demo highlights the value of technology like ours that supports interoperability and disaggregation.”

Conducted by TIP’s Converged Architectures for Network Disaggregation & Integration (CANDI) sub-group, the PoC proved that all components of an open optical network can be operated by a single SDN controller. By demonstrating unified management of the OLS, open terminals and optical planning tool, the demo paves the way for true open networking and a new model of infrastructure operations with operators taking over network integration and optimization processes. The demo utilized ADVA’s compact and modular FSP 3000 OLS. With its open interfaces, the OLS interworks seamlessly with third-party transceivers and supports the latest coherent transport innovation. It also featured ADVA’s Ensemble Controller network management system, which was specifically designed to help network operators break up network layers while moving towards a software-defined multi-vendor architecture. TIP partners collaborating with ADVA on the demo included the major network operators Orange, Telefónica and Telia Company.

“The success of TIP’s PoC offers a major boost to communication service providers looking to harness the benefits of increased agility and supplier diversity in their optical infrastructure. Our open technology gives network operators the opportunity to massively increase efficiencies by moving away from closed proprietary systems and towards vendor-neutral networking,” commented Stephan Neidlinger, VP, global business development, ADVA. “The TIP community has once again accomplished a significant step forward for open, disaggregated and standards-based connectivity technology. By collaborating closely with our partners in this project, our team has helped to accelerate the development of the next generation of communication networks, free from vendor lock-in and ready to connect tomorrow’s world.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye